
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc's promising outlook is supported by favorable safety and tolerability data for its lead candidate, epetraborole, which showed mild and reversible reductions in hemoglobin during Phase 2 trials. Positive clinical outcomes, including significant improvements in cough frequency and intensity for patients suffering from Mycobacterium avium complex non-tuberculous mycobacterial infections, underscore the drug’s potential impact on patient quality of life. Additionally, the encouraging pre-clinical data regarding epetraborole’s potential effectiveness against Mycobacterium abscessus, a more challenging target, positions AN2 Therapeutics to potentially expand its treatment offerings in a market with significant unmet medical needs.
Bears say
AN2 Therapeutics Inc. faces significant financial challenges, highlighted by a history of losses and the absence of profitability, which raises concerns about the sustainability of its operations. The company's recent setbacks in clinical trials, specifically with epetraborole, as well as the potential for litigation risks, further complicate its path to market. Additionally, the ongoing difficulty in establishing acceptable partnership terms for commercialization underscores a precarious position amid competitive market conditions and regulatory hurdles.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares